Companies: 10,795·Total market cap: $144.5T
Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

TAKNYSEHealthcare● Active
$15.84
+$0.24(+1.51%)
Market Cap$50.0B
P/E Ratio—
52W High$18.9
52W Low$12.99
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Takeda Pharmaceutical Company Limited (TAK) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001395064 · TAK · NYSE · as of Jun 8, 2026

Filing snapshot

625
Total Filings
6-K
Latest Form
2026-06-05
Most Recent
2010
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001395064 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2025-06-25
Fiscal Year End
Jun 25, 2025
Accession No.
0001395064-25-000095
Primary Document
tak-20250331.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001395064 · Accession 0001395064-25-000095

Latest Key Filings

6-KQuarterly Report
6-K
2026-06-05
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-05
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-05
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-01
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-26
View
SDSD
SD
2026-05-22
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-19
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-13
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-13
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-05-05
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-04-06
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-04-06
View
Showing 1–15 of 538 filingsForm 4 / 144 hidden· 625 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001395064  |  Exchange: NYSE · Healthcare

Takeda Pharmaceutical Company Limited (NYSE: TAK) has submitted 625 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2010. As a Healthcare sector company with CIK 0001395064, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Takeda Pharmaceutical Company Limited's most comprehensive regulatory disclosure. The most recent Takeda Pharmaceutical Company Limited 10-K was filed on 2025-06-25 for fiscal year ending 2025. Historical TAK 10-K annual reports are available from 2007 through 2025.

Investors researching Takeda Pharmaceutical Company Limited SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
BDX SEC Filings →EW SEC Filings →CAH SEC Filings →HLN SEC Filings →A SEC Filings →ALC SEC Filings →IQV SEC Filings →RMD SEC Filings →
→ TAK Financials→ TAK Earnings→ TAK Insider Trades

Frequently Asked Questions

TAK SEC Filings · 8 questions

Takeda Pharmaceutical Company Limited (TAK) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 625 filings and access original documents at no cost. Takeda Pharmaceutical Company Limited's CIK is 0001395064.

TAK SEC filingsTakeda Pharmaceutical Company Limited SEC documentsfind TAK 10-K